$PBLA News

Last published 1y ago

1y agoPBLAPanbela Provides Business Update and Reports Q3 2024 Financial ResultsGlobeNewswireMINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today
2y agoPBLAPanbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024GlobeNewswireMINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical
2y agoPBLAFirst Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer CenterGlobeNewswireMINNEAPOLIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today
2y agoPBLAPanbela Provides Business Update and Reports Q2 2024 Financial ResultsGlobeNewswireMINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today
2y agoPBLAPanbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024GlobeNewswireMINNEAPOLIS, July 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical
2y agoPBLAPanbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial ModificationGlobeNewswireDSMB Recommends Continuation without Modification for Third TimeSafety Review Included 395 PatientsInterim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate Low Event Rate Suggests
2y agoPBLAPanbela Announces Oral Presentation at Digestive Disease Week (DDW):GlobeNewswireMINNEAPOLIS, June 10, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today
2y agoPBLAPanbela Provides Business Update and Reports Q1 2024 Financial ResultsGlobeNewswireMINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today
2y agoPBLAPanbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and SulindacGlobeNewswireMINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today
2y agoPBLAPanbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024GlobeNewswireMINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical
2y agoPBLAAcceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease WeekGlobeNewswireMINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today
2y agoPBLAPanbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025GlobeNewswireMINNEAPOLIS, April 22, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical
2y agoPBLAPanbela Announces Poster Presentation at American Association for Cancer Research:GlobeNewswireMINNEAPOLIS, April 18, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA)("Panbela"), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with
2y agoPBLAPanbela Announces Transfer to OTCQB MarketGlobeNewswireMINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical
2y agoPBLAPanbela Provides Business Update and Reports Q4 and FY 2024 Financial ResultsGlobeNewswireMINNEAPOLIS, March 26, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today
2y agoPBLAPanbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024GlobeNewswireMINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical
2y agoPBLAPanbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares RequirementsGlobeNewswireMINNEAPOLIS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical
2y agoPBLAPanbela Announces Closing of Approximately $9.0 Million Public OfferingGlobeNewswireMINNEAPOLIS, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today
2y agoPBLAAcceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)GlobeNewswireMINNEAPOLIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today
2y agoPBLAPanbela Announces Pricing of Approximately $9.0 Million Public OfferingGlobeNewswireMINNEAPOLIS, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today
2y agoPBLAPanbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated MomentumGlobeNewswireInterim Data Analysis Anticipated in Mid-2024Expects Full Enrollment by Q1 2025 MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive
2y agoPBLAPanbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy TrialGlobeNewswireMINNEAPOLIS, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet
2y agoPBLAPanbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024GlobeNewswireMINNEAPOLIS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today
2y agoPBLAPanbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.0 Million Gross Proceeds Priced At-the-MarketGlobeNewswireMINNEAPOLIS, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet
2y agoPBLAPanbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric NeuroblastomaGlobeNewswireMINNEAPOLIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today
2y agoPBLAPanbela Announces Publication of Abstract Titled: Evaluation of Myeloma Cell Lines Viability Following Administration of SBP-101 and DFMO Polyamine InhibitorsGlobeNewswireMINNEAPOLIS, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today
2y agoPBLAPanbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial ModificationGlobeNewswireMINNEAPOLIS, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs,
3y agoPBLAPanbela Therapeutics, Inc. (PBLA) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
3y agoPBLAPanbela Provides Business Update and Reports Q3 2023 Financial ResultsGlobeNewswireMINNEAPOLIS, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today
3y agoPBLAPanbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds Priced At-the-MarketGlobeNewswireMINNEAPOLIS, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet
3y agoPBLAPanbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 DiabetesGlobeNewswireA Phase 1 clinical study showed that DFMO treatment may provide metabolic benefits to preserve β cell function and health in T1D. MINNEAPOLIS, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc.
3y agoPBLAPanbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101GlobeNewswireMINNEAPOLIS, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet
3y agoPBLAAcceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online PublicationGlobeNewswireMINNEAPOLIS, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today
3y agoPBLAPanbela to Host Third Quarter 2023 Earnings Conference Call on November 9, 2023GlobeNewswireMINNEAPOLIS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today
3y agoPBLAPanbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101GlobeNewswireMINNEAPOLIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- (NASDAQ:PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today
3y agoPBLAPanbela to Present at the LD Micro Investor ConferenceGlobeNewswireMINNEAPOLIS, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet
3y agoPBLAPanbela Announces Issuance of New Patent in Chile for Claims of a Novel Process for the Production of FlynpoviGlobeNewswireMINNEAPOLIS, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet
3y agoPBLAPanbela to Present at H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewswireMINNEAPOLIS, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet
3y agoPBLAPanbela Announces Issuance of New Patent in Europe for Claims of a Novel Process for the Production of SBP-101GlobeNewswireMINNEAPOLIS, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet
3y agoPBLAPanbela Provides Business Update and Reports Q2 2023 Financial ResultsGlobeNewswireMINNEAPOLIS , Aug. 10, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today
3y agoPBLAPanbela to Host Second Quarter 2023 Earnings Conference Call on August 10, 2023GlobeNewswireMINNEAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today
3y agoPBLAPanbela Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer, All Countries/Regions in the Aspire Trial are Now Open and Actively EnrollingGlobeNewswireMINNEAPOLIS, July 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today
3y agoPBLAPanbela Therapeutics to Receive a Total Up to $9.5 Million for Divestiture of Assets within Eflornithine (DFMO) Pediatric Neuroblastoma Program to US WorldMedsGlobeNewswireMINNEAPOLIS and LOUISVILLE, Ky., July 19, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet
3y agoPBLAPanbela Announces Issuance of New Patent in Australia Patent is for Claims of a Novel Process for the Production of SBP-101GlobeNewswireMINNEAPOLIS, July 17, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet
3y agoPBLAPanbela Announces Preliminary Safety Analysis for ASPIRE TrialGlobeNewswireMMINNEAPOLIS, July 10, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs,
3y agoPBLAPanbela Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility AnalysisGlobeNewswireMINNEAPOLIS, June 28, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today
3y agoPBLAPanbela Announces Poster Presentation at the Endocrine Society Meeting: Polyamine Inhibition and β-Cell Preservation in Recent Onset Type 1 DiabetesGlobeNewswireMINNEAPOLIS, June 26, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet
3y agoPBLAPanbela Announces Closing of Approximately $8.5 Million Public OfferingGlobeNewswireMINNEAPOLIS, June 21, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today
3y agoPBLAPanbela Announces Pricing of Approximately $8.5 Million Public OfferingGlobeNewswireMINNEAPOLIS, June 16, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today
3y agoPBLAPanbela Announces Sponsored Research Agreement to Evaluate Polyamine Metabolic Inhibitor Therapy in Combination with CAR-T Cell TherapyGlobeNewswireMINNEAPOLIS, June 13, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today